A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1

Sponsor
NYU Langone Health (Other)
Overall Status
Completed
CT.gov ID
NCT02974335
Collaborator
Icahn School of Medicine at Mount Sinai (Other), Oregon Health and Science University (Other), Massachusetts General Hospital (Other)
104
3
20.3
34.7
1.7

Study Details

Study Description

Brief Summary

This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care providers to offer appropriate interventions by providing clinical decision support (CDS) and a mechanism for making referrals to addiction treatment. We aim to maximize the efficient adoption of screening, CDS, and treatment referrals by integrating all of these activities into the electronic health record (EHR).

The study will be conducted at three sites, representing three large health systems. Each phase will include deliverables essential to move to the next phase, and an independent Advisory Committee will review progress and make recommendations at each transition about how best to progress to each subsequent phase. Based on progress during earlier phases, the Advisory Committee may recommend expansion to additional clinics or health systems during the second part of Phase 4.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Interviews with Stakeholders

Detailed Description

Phase 1 involves identifying the optimal screening tools and approaches for capturing CDE data, programming the screening tools and CDEs into the Epic EHR, and soliciting stakeholder input regarding implementation strategies for screening and clinical interventions (including treatment referrals) to address substance use.

In the KTA framework, Phase 1 addresses the first steps in the action cycle, which are to identify, review, and select the tools that are to be implemented; adapt tools to the local context; assess barriers to use of the tools; and begin the process of implementation by programming these tools into the Epic EHR. We will accomplish these steps primarily through interviews and focus groups with key stakeholders. The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.

Research Questions and Aims

The research questions that Phase 1 seeks to address are:
  1. Where should screening and initial assessment occur, and who should administer the screening and assessment questionnaires?

  2. Is it better to screen for drugs only, or for drugs and alcohol, or for drugs, alcohol and tobacco? Should screening also include depression (e.g., PHQ2 and PHQ9)? Should screening be embedded in a broad behavioral health screen (e.g., a comprehensive health risk assessment such as My Own Health Report (30))?

The specific aim that corresponds to Phase 1 is Aim 1: To program the NIDA CTN CDEs and a lean decision support module into Epic. This phase will also define potential barriers and facilitators to the adoption of the CDEs and CDS, which is a component of Specific Aim 2.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
104 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1
Actual Study Start Date :
Jul 25, 2017
Actual Primary Completion Date :
Apr 5, 2019
Actual Study Completion Date :
Apr 5, 2019

Arms and Interventions

Arm Intervention/Treatment
Identify screening and intervention approaches

Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.

Behavioral: Interviews with Stakeholders
The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.

Outcome Measures

Primary Outcome Measures

  1. Patient level outcomes: diagnosis, and treatment referral [1 Year]

  2. Provider level outcomes: screening and assessment, and clinical interventions including counseling and treatment referral. [1 year]

  3. Systems level outcomes: logistics and costs of introducing the CDEs. [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Must be a current primary care clinic patient
Exclusion Criteria:
  • Inability to provide informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusettes General Hospital Boston Massachusetts United States 02114
2 Icahn School of Medicine at Mount Sinai New York New York United States 10029
3 Oregon Health and Science University Portland Oregon United States 97239

Sponsors and Collaborators

  • NYU Langone Health
  • Icahn School of Medicine at Mount Sinai
  • Oregon Health and Science University
  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Jennifer McNeely, New York University Medical School

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
NYU Langone Health
ClinicalTrials.gov Identifier:
NCT02974335
Other Study ID Numbers:
  • 14-01948
First Posted:
Nov 28, 2016
Last Update Posted:
Aug 9, 2019
Last Verified:
Aug 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2019